The Executive Management and the Board of Directors gather professionals of the pharmaceutical and biotech industry as well as finance.

Zopamavi SAS, represented by Louis Champion

Louis Champion 96853

MD, graduated from Lyon (France) medical school, and MBA from INSEAD, Louis Champion spent all his professional career in health sector, mostly in biologicals. He started at Pasteur-Mérieux-Connaught (currently SANOFI Pasteur) in the 90’s, reporting to the CEO and setting up the strategic marketing group. From 1995 to 2000, he served as general manager of the Brazilian subsidiary.

In 2000, he joined Stallergènes, a pharmaceutical allergen company listed on Paris Stock exchange as COO, strongly contributing to the company’s growth and development until 2011. In 2011, as chairman and CEO, he led the turn-around of IPSanté, a leading health homecare company in France, that successfully underwent a secondary LBO in 2016. On behalf of the shareholders, he retained the chairmanship of the holding company of Elivie/IPSanté.

He is Board member of several companies in private primary care, biotechnology and medical device sectors. 

Michel Baijot

Michel Baijot fddd0

Bioengineer, PhD, Michel Baijot is a life science executive bringing over 25 years of experience in building biologicals businesses with significant contribution in strategy, licensing, M&A and technology transfer.

His positions with biotech and big pharmaceutical companies as well as his tangible achievements reflect an in-depth knowledge of the business environment in both developed and emerging markets.

He is currently Board Director of IRE-Elit, the RadioPharma Division of IRE, and Board Director of OncoRadiomics. His previous positions include Executive Director Europe at Serum Institute of India, Head of Cipla Global Vaccine, Chief Business Officer at Janssen/Crucell, Vice President Worldwide Strategic Alliances and Business Development at GlaxoSmithKline Biologicals and Vice President Business Development at Innogenetics. He was Chairman of the Belgian Biotech Association during 5 years.

François Meurgey


As managing Partner of Oukelos, François is working as independent consultant in pharmaceutical product strategic marketing. He spent more than twenty-five years in the biopharmaceutical industry, both in Europe and the United States, and holding both operational and higher management functions like Director of Global Marketing for Prozac® at Eli Lilly, Senior Director of Asia-Pacific Marketing at Merck & Co. and Vice-President of Global Marketing at UCB. François graduated from Reims Management School, received a master degree in International Relations from University of Paris-Sorbonne and holds an MBA from the Stern School of Business, New York University.

Everard van der Straten


Everard van der Straten holds a master from Solvay Business School. After a short career as auditor at Arthur and Anderson & Co, Everard was managing director of Metallo-Chimique Group and afterwards Board Member of the Metallum Group until end 2008. Currently, Everard is as well Business Angel.

Noshaq Partners SCRL, represented by Philippe Degeer

Philippe Degeer c6f65

Industrial engineer (Haute Ecole Libre Mosane – HELMo Gramme) and holder of an MBA from the London Business School, Philippe Degeer first worked for a SME in Liège and then developed his career within the American multinational Goodyear Dunlop. After becoming Vice President of the group in Europe, Africa and the Middle East, he oversaw the implementation of innovation processes, international development policies as well as BtoB and BtoC marketing strategies. He has implemented corporate governance oriented towards investment and growth. He has also participated in the development of various partnerships, mergers, acquisitions and technology transfers.

Philippe Degeer is Chairman of the Board of Directors of AMOS and is a Board member of Diagenode, Endotools, EyeDPharma and Lasea.

SFPI – FPIM represented by François Fontaine

Francois Fontaine web

Master degree in law and tax sciences, François Fontaine is a General Counselor at the Belgian Federal Investment and participation Company (SFPI) since December 2009. He is in charge of investment projects in the fields of new technologies, biomedical, real estate, waste, water treatment and energy sector. He was previously advisor to the tax unit of the Walloon Region in charge of the implementation and transfer of regional taxes.

RE Finance Consulting SA represented by Yves Désiront


Yves Désiront is the Managing Partner of a private equity fund based in Luxembourg and is acting, since October 2014, as Group CFO under a consulting contract with BGP Investment, a Luxembourg real estate group based in Luxembourg. Previously he acted as Group CFO of Orco Property Group. Prior to this he served in various roles at Groupe Bruxelles Lambert and Générale de Banque. Yves Désiront obtained in 1994 a master degree as Ingénieur Commercial in Business Administration and Technology Interface from I.C.H.E.C. Brussels.

Harry Welten


Harry Welten, MBA, spent more than twenty years in international senior executive functions, fifteen of which as chief financial officer in biotechnology companies (privately as well as publicly held). He was involved in IPO’s, mergers and acquisitions and raised more than CHF 320 million from private and public investors. He holds a degree in banking and finance, a degree in economics and business administration and an MBA (Hons.) from Columbia University, New York. 

He serves as Chairman of the Board of Directors of Novaremed AG as well as of BiognoSYS AG, and is a member of the Board of Directors of Kanyos, ProteoMediX, Virometix and Horizon Pharma AG. Harry is also a member of the foundation council of HBM Fondation.

Jean-Paul Prieels

Asitbiotech Jean Paul Prieels 58297
Jean-Paul Prieels received his PhD in Biochemistry from the University of Brussels. He worked at GSK for over 23 year, having most recently served as Senior Vice President of R&D for GSK Vaccines and formerly worked at Smith Kline RIT. Jean-Paul joined the pharmaceutical sector after spending 13 years in academia (ULB, Duke University, ICP-UCL) and 3 years at Oléofina, a subsidiary of Petrofina. In 2011, he left GSK for the biotechnology industry to serve as founder, investor, board member and scientist. He currently serves as a Director of Bone Therapeutics, DNALytics, MastherCell, Ncardia, Paracrine Biologicals and PDC Line Pharma in Belgium, Nouscom in Switzerland, Themis in Austria and Leukocare in Germany. He is also a member of scientific advisory boards of Abivax, CureVac, Imcyse and Vaximm.